T3D Therapeutics
Mr. Mendell is a Private Investor and serves on the boards of directors of several private companies. Mr. Mendell was a partner of JPMorgan Partners from 2000 to 2003 and a partner of The Beacon Group, a merchant bank, from March 1994 to July 2000. Prior to joining The Beacon Group, Mr. Mendell was a Partner of Goldman, Sachs & Co. where he served as a member of the firm’s Investment Committee and Head of GS Capital. Mr. Mendell had shared responsibility for making principal investments of the firm’s capital as well as for the Broad Street Fund and GS Capital Partners, L.P. Mr. Mendell also spent eleven of his nineteen years at Goldman Sachs in the Mergers & Acquisitions Department where he successfully completed over one hundred fifty transactions for clients in a wide array of industries. Before joining Goldman Sachs, he was an officer in the United States Navy.
Mr. Mendell is currently Chairman of SonaCare Medical, LLC, Chairman of Knowledge Delivery Systems, Inc., and a director of several private companies, including TopGolf International, Inc., Provista Diagnostics, Inc., and ZeroWater Technologies, LLC. In addition, he is on the board of the Cancer Research Institute, MENTOR/National Mentoring Partnership, and has served on the Harvard Business School Alumni Board and as a Trustee of St. Bernard’s School.
Mr. Mendell is a graduate of Harvard University (M.B.A.) and Vanderbilt University (B.E.).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
T3D Therapeutics
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.